- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Republication of this report in part or in its entirety is welcome, with the following credit line: "Content was reprinted from AVAC Report 2013: Research & Reality published by AVAC (www.avac.org)."
Page 3 — The HIV Prevention Research-to-Rollout Continuum, December 2013
Page 4 — A Three-Part Agenda for Ending AIDS
Page 7 — Our Top-Line Recommendations for Women's Prevention Research
Page 8 — AVAC Playbook 2013–2014: Global goals and priorities
Page 10 — Effectiveness and Adherence in Trials of Oral and Topical Tenofovir-Based Prevention
Page 11 — Clinical Trial Evidence for Oral and Topical Tenofovir-Based Prevention, December 2013
Page 13 — ARV-Based Prevention Pipeline, December 2013
Page 15 — Dimensions of Adherence
Page 16 — Trials of Tenofovir-Based Prevention Methods: At-a-glance
Page 18 — Vaginal Rings: Products in development for HIV prevention and multipurpose technologies
Page 20 — Biomedical HIV Prevention Efficacy Trials, 2014–2016
Page 22 — RV144 Follow-on Trials: Lagging timelines
Page 23 — AIDS Vaccine Research: An overview, December 2013
Page 24 — Up Close: The meta-analysis of Ad5 candidates
Page 29 — Use of Injectable Contraceptives and HIV Acquisition: The data to-date
Page 31 — Planned PrEP Demonstration Projects in Resource-Poor Settings, November 2013
Page 32 — Progress in VMMC Scale-up in Priority Countries, Through 2012
Page 32 — Counting Cuts: Getting better at monitoring VMMC
Page 33 — Voluntary Medical Male Circumcision (VMMC) Device Evaluations
Page 35 — Viral Load Testing Delivers Systemic Benefits from the Individual to the Institution
Page 37 — The Global HIV Treatment Gap: Existing people on ART versus people eligible under past and current WHO guidelines
Page 38 — 2013 WHO ARV guidelines can decrease new infections and deaths
Page 39 — From Research to Rollout: Evaluations that move a product to the "real world"
Page 41 — The Tipping Point: Understanding a crucial milestone in the AIDS response
Page 43 — Global Prevention Research Advocacy Partnerships